Abeona Therapeutics Inc. (ABEO)Healthcare | Biotechnology | Cleveland, United States | NasdaqCM
7.01 USD
+0.03
(0.430%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 7.01 |
Hot Take ↕ | July 11, 2026, 6:08 a.m. EDT
The fundamental reality here is stark: this biotech stock is in a structural freefall, having lost over 90% of its value since 2016. Despite a recent technical bounce off the lows, the underlying business is bleeding cash, with gross margins in negative territory and operating cash flow draining reserves at a rapid pace. The balance sheet is fragile, with debt-to-equity nearing 16x and no dividend to provide any cushion. While the price has stabilized recently, the lack of consecutive positive years and the persistent negative earnings trajectory suggest the market views this as a value trap rather than a bargain. The options market reflects this tension, with traders buying cheap insurance against further drops while dreaming of a miraculous turnaround to hit distant strike prices. For a serious investor, the combination of deteriorating fundamentals, cash burn, and a precarious balance sheet makes this a dangerous hold. The recent price action is merely a pause in a longer-term decline, and without a proven pipeline milestone or capital raise, the odds favor further downside. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.093401 |
| MSTL | 0.093799 |
| MSTL_48 | 0.094734 |
| AutoTheta | 0.098790 |
| AutoARIMA | 0.106827 |
| MSTL_79 | 0.110479 |
| MSTL_48_79 | 0.110550 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 4.01 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2000-03-30 |
| Debt to Equity Ratio | 15.988 |
| Revenue per Share | 0.266 |
| Market Cap | 399,535,968 |
| Trailing P/E | 7.38 |
| Forward P/E | 24.45 |
| Beta | 1.33 |
| Profit Margins | 454.86% |
| Website | https://www.abeonatherapeutics.com |
As of July 11, 2026, 6:08 a.m. EDT: Speculators are positioning for a volatile range-bound outcome rather than a directional breakout. Call volume is heavily skewed toward out-of-the-money strikes (10.00) for later expirations, suggesting a speculative hope for a rally, while put volume concentrates at lower strikes (5.00, 6.00) acting as a floor. The massive implied volatility gap between the July 17th expiration (10.52% IV for puts vs 1.85% for calls) indicates extreme fear regarding a near-term dip, whereas the August expiration shows normalized pricing with heavy OTM call interest. This asymmetry suggests traders are hedging against a drop while retaining a lottery ticket mentality for a recovery.
| Date | Dividend | Yield % |
|---|---|---|
| 2000-03-31 | 3706.25 | 8.547748 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.17905402 |
| Address1 | 6,555 Carnegie Avenue |
| Address2 | 4th Floor |
| All Time High | 5,437,500.0 |
| All Time Low | 0.27 |
| Ask | 8.58 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 1,900,360 |
| Average Daily Volume3 Month | 1,184,540 |
| Average Volume | 1,184,540 |
| Average Volume10Days | 1,900,360 |
| Beta | 1.33 |
| Bid | 5.08 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 2.549 |
| City | Cleveland |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.01 |
| Current Ratio | 5.894 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 7.085 |
| Day Low | 6.66 |
| Debt To Equity | 15.988 |
| Display Name | Abeona Therapeutics |
| Earnings Call Timestamp End | 1,778,675,400 |
| Earnings Call Timestamp Start | 1,778,675,400 |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -90,049,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.826 |
| Enterprise To Revenue | 17.499 |
| Enterprise Value | 254,437,952 |
| Eps Current Year | -0.68333 |
| Eps Forward | 0.28667 |
| Eps Trailing Twelve Months | 0.95 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.7622 |
| Fifty Day Average Change | 1.2478004 |
| Fifty Day Average Change Percent | 0.2165493 |
| Fifty Two Week Change Percent | 17.905403 |
| Fifty Two Week High | 7.54 |
| Fifty Two Week High Change | -0.52999973 |
| Fifty Two Week High Change Percent | -0.07029174 |
| Fifty Two Week Low | 4.0 |
| Fifty Two Week Low Change | 3.0100002 |
| Fifty Two Week Low Change Percent | 0.75250006 |
| Fifty Two Week Range | 4.0 - 7.54 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 338,218,200,000 |
| Float Shares | 36,615,960 |
| Forward Eps | 0.28667 |
| Forward P E | 24.453205 |
| Free Cashflow | -56,589,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 226 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -1.23845 |
| Gross Profits | -18,007,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16588 |
| Held Percent Institutions | 0.70515996 |
| Implied Shares Outstanding | 56,995,144 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.accesspharma.com/investor-relations/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 954,460,800 |
| Last Dividend Value | 3,706.25 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,656,979,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio. |
| Long Name | Abeona Therapeutics Inc. |
| Market | us_market |
| Market Cap | 399,535,968 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_360935 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 66,137,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 397,826,105 |
| Number Of Analyst Opinions | 7 |
| Open | 6.98 |
| Operating Cashflow | -77,728,000 |
| Operating Margins | -2.6414 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 646 813 4701 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 7.01 |
| Post Market Time | 1,783,983,654 |
| Previous Close | 6.98 |
| Price Eps Current Year | -10.258587 |
| Price Hint | 2 |
| Price To Book | 2.7500982 |
| Price To Sales Trailing12 Months | 27.478403 |
| Profit Margins | 4.54862 |
| Quick Ratio | 5.636 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0300002 |
| Regular Market Change Percent | 0.429802 |
| Regular Market Day High | 7.085 |
| Regular Market Day Low | 6.66 |
| Regular Market Day Range | 6.66 - 7.085 |
| Regular Market Open | 6.98 |
| Regular Market Previous Close | 6.98 |
| Regular Market Price | 7.01 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,444,431 |
| Return On Assets | -0.38924998 |
| Return On Equity | 0.70987 |
| Revenue Per Share | 0.266 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 56,995,144 |
| Shares Percent Shares Out | 0.24 |
| Shares Short | 13,680,180 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 14,393,465 |
| Short Name | Abeona Therapeutics Inc. |
| Short Percent Of Float | 0.2577 |
| Short Ratio | 11.22 |
| Source Interval | 15 |
| State | OH |
| Symbol | ABEO |
| Target High Price | 28.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 19.71429 |
| Target Median Price | 20.0 |
| Total Cash | 168,271,008 |
| Total Cash Per Share | 2.952 |
| Total Debt | 23,173,000 |
| Total Revenue | 14,540,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.95 |
| Trailing P E | 7.3789477 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.231 |
| Two Hundred Day Average Change | 1.7790003 |
| Two Hundred Day Average Change Percent | 0.34008798 |
| Type Disp | Equity |
| Volume | 1,444,431 |
| Website | https://www.abeonatherapeutics.com |
| Zip | 44,103 |